ICON PLC (ICLR)

ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee InvestigationMay 27, 2026 4:33 PM
Business Wire Highlights Quarter four revenue was $2,112.5 million. Full year revenue was $8,251 million. Quarter four adjusted EBITDA of $327.1 million or 15.5% of revenue; full year adjusted EBITDA of $1,530.7 million or 18.6% of revenue. GAAP net income for the quarter of $149.2 million or $1.93 per diluted share. Full year GAAP net income of $229.3 million or $2.90 diluted earnings per share. Quarter four adjusted net income of $195.1 million or $2.52 diluted earnings per share; full year adjusted net income of $989.8 million or $12.53 diluted earnings per share. Net business wins in the quarter of $2,868 million; a net book to bill ratio of 1.36. Full year net business wins of $9,033 million; a net book to bill of 1.09. Strong bookings momentum with quarter four gross business wins of $3,233 million and cancellations of $365 million. Net debt balance of $2.8 billion at December 31, 2025 with net debt to adjusted EBITDA ratio of 1.8x. Free cash flow of $862.0 million for 2025. The Audit Committee's investigation into certain accounting practices is complete. The Company is restating its consolidated financials to reflect that revenue was overstated by 0.8% of total revenue in full year 2023, and by 1.1% of total revenue in full year 2024. There was no impact on customers, operations, or cash flow. Independent from the investigation, management has amended policies and methodologies on cancellations and backlog recognition to provide enhanced visibility into metrics that are relevant to assess current and future financial performance. 2026 full-year financial guidance issued with revenue expected in the range of $7,850 - $8,150 million and adjusted diluted earnings per share expected in the range of $10.00 - $11.00. Adjusted diluted earnings per share to exclude amortization, stock-based compensation, foreign currency gains and losses, restructuring, transaction, integration-related and other adjustments, transaction-related financing costs, fair value movement on investments in equity, goodwill impairment, impairment of non-financial assets and their related taxation effect. ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today reported its financial results for the fourth quarter and full year 2025, and announced the outcome of its investigation by the Audit Committee of the Board of Directors into certain accounting practices. CEO, Mr. Barry Balfe commented, “ICON demonstrated continued commercial momentum through the fourth quarter, underpinned by disciplined execution against our strategic priorities. We achieved notably strong net bookings, with gross awards strengthening, cancellations normalizing and forward-looking indicators encouraging. Our competitive position remains very strong, with established partnerships continuing to deliver, while newer relationships are maturing and increasingly contributing to results. Importantly, the demand environment is also improving, supported by strengthening biotech funding and sustained large pharma investment. I am also pleased that we have concluded the investigation into certain accounting practices. We identified the issues, rigorously investigated them and are actively building a stronger control environment. This will remain a priority for me, for our Board and for the broader leadership team. Looking ahead, ICON retains a positional advantage in the drug development industry. Our leading scale, capabilities and customer base are augmented by our strategic investments in differentiated agentic technologies. While near-term financial performance will reflect the headwinds identified in 2025, increasing commercial momentum and a maturing portfolio of strategic partnerships point to sustainable growth into 2027 and beyond." Fourth Quarter 2025 Results In quarter four 2025, gross bookings were $3,233 million with cancellations of $365 million. This resulted in net business wins of $2,868 million and a book to bill of 1.36. Revenue for the fourth quarter was $2,112.5 million. This represents an increase of 2.5% on prior year revenue or 1.1% on a constant currency basis. GAAP net income was $149.2 million, resulting in diluted earnings per share of $1.93 in quarter four 2025, compared to diluted earnings per share of $3.58 in quarter four 2024, a decrease of 46.1% year over year. Adjusted net income for the quarter was $195.1 million, resulting in adjusted diluted earnings per share of $2.52 compared to $3.86 per share for the fourth quarter 2024. Adjusted EBITDA for the fourth quarter was $327.1 million or 15.5% of revenue. The effective tax rate on adjusted net income in quarter four 2025 was 19.0%. Cash generated from operating activities for the quarter was $234.2 million. During the quarter, $59.3 million was spent on capital expenditure. Additionally, $7.4 million of Term Loan B payments were made during the quarter. At December 31, 2025, the Group had cash and cash equivalents of $647.3 million, compared to cash and cash equivalents of $468.9 million at September 30, 2025 and $538.8 million at December 31, 2024. Net indebtedness as at December 31, 2025 was $2.8 billion. Backlog Reporting Enhancements The Company has decided to adjust how it calculates and presents cancellations and its backlog. The changes implemented are intended to provide enhanced visibility into reported metrics that are relevant to assess current and future performance of the business. Effective October 1, 2025, ICON modified its cancellations policy, such that reported quarterly cancellation amounts now reflect in-period cancellation notifications from customers, in addition to studies that have been inactive, or identified by management as at-risk for cancellation. There is no change to ICON's treatment of awards and their recognition into backlog. These policy changes resulted in an adjustment to reported backlog of $3.9 billion, resulting in an updated backlog value of $21.1 billion, as of October 1, 2025. Full Year 2025 Results and 2026 Guidance Gross business wins were $11,867 million and cancellations were $2,834 million, as determined under the new policy. This resulted in net business wins of $9,033 million and a book to bill of 1.09. As of December 31, 2025, under the new methodology, total backlog was $21.8 billion. Full year revenue was $8,251.3 million. This represents a year on year increase of 0.8% or 0.1% on a constant currency basis. GAAP net income was $229.3 million, resulting in $2.90 diluted earnings per share compared to $8.90 per share for the equivalent prior year period, representing a decrease of 67.4%. Adjusted net income was $989.8 million, resulting in an adjusted diluted earnings per share of $12.53 compared to $13.37 per share for the equivalent prior year period. This represents a decrease of 6.3%. Adjusted EBITDA was $1,530.7 million or 18.6% of revenue, a year on year decrease of 8.4%. The effective tax rate on adjusted net income in 2025 was 16.9%. Cash generated from operating activities in 2025 was $1,036.2 million. $174.2 million was spent on capital expenditure. $750.0 million worth of stock was repurchased at an average price of $167 per share. Additionally, $29.8 million of Term Loan B payments were made. The Company is issuing full-year financial guidance for 2026 with revenue expected in the range of $7,850 - $8,150 million, and adjusted diluted earnings per share expected in the range of $10.00 - $11.00. Conclusion of Investigation and Restatement of Financial Statements The Audit Committee of the Board of Directors has completed its previously announced investigation into certain accounting practices and controls, initiated following concerns reported through Company management. The investigation primarily focused on revenue recognition practices and concluded that improper adjustments were made to the clinical trial services revenue of the Company from the third quarter of 2023 to the fourth quarter of 2024, which impacted the timing of revenue recognition. The Company also identified errors in determining the estimated cost to complete, the assessment of realizable value, and certain manual adjustments in respect of clinical trial services revenue contracts during 2023, 2024 and 2025. The Company also identified issues with the presentation of unbilled and unearned revenue, where contract assets and liabilities eligible for offset were not fully identified. As described in the Form 20-F, the Company has concluded that revenue was overstated by $65.3 million for the year ended December 31, 2023 (0.8% total revenue) and by $92.7 million for the year ended December 31, 2024 (1.1% of total revenue). As part of the investigation, ICON identified material weaknesses in its internal control over financial reporting. The Company’s entity level controls, including the tone from management, were insufficient to enforce the monitoring and maintenance of a proper environment for effective internal control over financial reporting. Management did not design and operate effective internal controls to prevent material errors to revenue and related accounts. The Company’s current management, under the oversight of the Audit Committee, is committed to remediating the material weaknesses identified above, fostering continuous improvement in internal controls and enhancing its overall internal control environment. The Company’s remediation plan includes enhancements in relation to four key areas: oversight of control environment, policies and procedures, training and internal controls over manual adjustments. The 2025 Annual Report on Form 20-F contains additional details regarding the material weaknesses and actions the Company have taken and continue to take to remediate the identified material weaknesses. Board of Directors Update The Company also announced that Mr. Kevin Egan and Mr. Jeff Elliott will join ICON's Board of Directors, effective June 1, 2026 and that Dr. Steve Cutler resigned from the Board effective May 21, 2026. Mr. Kevin Egan brings a wealth of experience, notably in auditing, after completing a 37-year career in public auditing, including leading PwC Ireland's audit and assurance practice from 2007 - 2015. He also currently serves as non-executive director and Chair of the Audit Committee at Perrigo plc. Mr. Jeff Elliott also brings a significant amount of expertise and financial depth, from previous leadership and operational roles. He was Chief Financial Officer of Exact Sciences Corp. from 2016 to 2024, and also served as Chief Operating Officer from 2021 to 2023. Prior to his roles at Exact Sciences, Jeff was a senior equity research analyst covering healthcare companies at Robert W. Baird & Co. Additionally, Jeff currently serves as non-executive director on the Boards of Quanterix, Inc. and Sera Prognostics. Mr. Ciaran Murray, Chairman of the Board, commented, "The Board of ICON is committed to the highest standards of corporate governance and is satisfied that the investigation into certain accounting practices conducted by the Audit Committee on the Board's behalf is complete. A remediation plan to address control weaknesses has been developed by Management and its implementation will be subject to oversight by the Audit Committee. I am also pleased to announce the appointment of Mr. Kevin Egan and Mr. Jeff Elliott to the Board effective June 1, 2026. Their extensive knowledge and expertise across financial-related matters, as well as experience in the healthcare industry, will serve to further strengthen the Board's support of ICON's long-term strategy and growth ambition." Conference Call Details ICON will hold a conference call on May 28, 2026 at 08:00 EDT [13:00 Ireland & UK]. This call and linked slide presentation can be accessed live from our website at http://investor.iconplc.com. A recording will also be available on the website for 90 days following the call. In addition, a calendar of company events, including upcoming conference presentations, is available on our website, under “Investors”. This calendar will be updated regularly. Other Information Cautionary Statement Regarding Forward-Looking Statements Certain statements contained herein are forward-looking statements. All statements other than statements of historical fact are forward-looking. Examples of forward-looking statements include, but are not limited to, statements regarding the following: anticipated financial results for 2026; the remediation of material weaknesses in the Company's internal control over financial reporting and the implementation of the Company's corrective action plan; the Company's expectations regarding business momentum, demand trends, commercial performance and competitive position; and the Company's expectations with respect to its long-term value creation and growth. You can identify many forward-looking statements by words such as “aims,” “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “focused,” “guidance,” “intends,” “look,” “may,” “opportunities,” “plans,” “position,” “potential,” “predicts,” “projects,” “seeks,” “should,” “will,” “would” and other similar expressions and the negatives of such expressions. However, not all forward-looking statements contain these words. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. Actual results may differ materially from those stated or implied by forward-looking statements due to risks and uncertainties associated with the Company's business, and forward-looking statements are not guarantees of future performance. Such risks and uncertainties include, but are not limited to: dependence on the pharmaceutical industry and certain clients; the need to regularly win projects and then to execute them efficiently and correctly; the challenges presented by rapid growth; competition and the continuing consolidation of the industry; the impact of market conditions on demand for the Company's services; risks related to the Company’s ability to execute on its commercial strategy and maintain relationships with large pharmaceutical customers; risks relating to the Company's strategic partnerships; the dependence on certain key executives; changes in the regulatory environment; exchange rate fluctuations; inflation and rising labor costs; the risk that material weaknesses in the Company's internal control over financial reporting are not remediated on the timeline expected or at all; the risk that the remediation measures and the corrective action plan do not adequately address the identified material weaknesses; and other factors, including those factors described in the section entitled “Risk Factors” of our Annual Report on Form 20-F most recently filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise, except to the extent required by law. Non-GAAP Financial Measures In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release contains certain non-GAAP financial measures, including adjusted EBITDA, adjusted net income and adjusted diluted earnings per share and free cash flow. Adjusted EBITDA excludes stock-based compensation, foreign currency gains and losses, restructuring, transaction, integration-related and other adjustments, fair value movement on investments in equity, and goodwill impairment, impairment of non-financial assets. Adjusted net income and adjusted diluted earnings per share exclude amortization, stock-based compensation, foreign currency gains and losses, restructuring, transaction, integration-related and other adjustments, transaction-related financing costs, fair value movement on investments in equity, goodwill impairment, impairment of non-financial assets and their related taxation effect. Free cash flow reflects cash generated from operating activities less capital expenditure. While non-GAAP financial measures are not superior to or a substitute for the comparable GAAP measures, ICON believes certain non-GAAP information is useful to investors for historical comparison purposes. *Our full-year 2026 guidance adjusted diluted earnings per share measures are provided on a non-GAAP basis without a reconciliation to the most directly comparable GAAP measure because the Company is unable to predict with a reasonable degree of certainty certain items contained in the measures without unreasonable efforts. For the same reasons, the Company is unable to address the probable significance of the unavailable information. ICON plc is a world-leading clinical research organization. Offering deep operational and medical expertise we accelerate innovation, driving emerging therapies forward to improve patient outcomes. From molecule to medicine, we deliver integrated consulting, clinical development, commercialization and post-marketing solutions to pharmaceutical, biotechnology, medical device, government and public health organizations worldwide. With headquarters in Dublin, Ireland, ICON employed approximately 40,100 employees in 97 locations in 55 countries as at December 31, 2025. For further information about ICON, visit: www.iconplc.com. ICON/ICLR-F   ICON plc CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2025 AND DECEMBER 31, 2024 AND DECEMBER 31, 2023 (UNAUDITED)     Three Months Ended December 31   Year ended December 31,     2025     2024 (As Restated)   2023 (As Restated)     2025     2024 (As Restated)   2023 (As Restated)   (in thousands, except share and per share data)                         Revenue $ 2,112,517     $ 2,061,867     $ 2,040,603     $ 8,251,340     $ 8,188,990     $ 8,054,926                           Costs and expenses:                       Direct costs   1,631,779       1,429,127       1,442,117       6,075,746       5,818,061       5,706,187   Selling, general and administrative   179,700       151,445       195,560       780,139       728,348       768,559   Depreciation and amortization   90,290       96,655       149,733       382,996       488,500       585,950   Transaction and integration related   6,128       7,907       9,660       25,269       29,574       44,176   Restructuring   (3,227 )     46,334       —       79,069       92,123       45,390   Goodwill impairment   —       —       —       364,248       —       —   Impairment of non-financial assets   —       —       —       101,027       —       —   Total costs and expenses   1,904,670       1,731,468       1,797,070       7,808,494       7,156,606       7,150,262                           Income from operations   207,847       330,399       243,533       442,846       1,032,384       904,664   Interest income   1,492       3,008       1,720       7,109       8,609       5,014   Interest expense   (49,487 )     (51,429 )     (81,034 )     (197,490 )     (237,237 )     (336,699 )                         Income before income tax (expense) / benefit   159,852       281,978       164,219       252,465       803,756       572,979   Income tax (expense) / benefit   (10,658 )     12,767       19,166       (23,126 )     (64,630 )     (18,388 )                         Income before share of earnings from equity method investments   149,194       294,745       183,385       229,339       739,126       554,591   Share of equity method investments   —       —       —       —       —       (383 ) Net income $ 149,194     $ 294,745     $ 183,385     $ 229,339     $ 739,126     $ 554,208                           Net income per ordinary share:                                               Basic $ 1.95     $ 3.60     $ 2.23     $ 2.92     $ 8.96     $ 6.75   Diluted $ 1.93     $ 3.58     $ 2.21     $ 2.90     $ 8.90     $ 6.70                           Weighted average number of ordinary shares outstanding:                                               Basic   76,522,983       81,785,620       82,399,478       78,423,675       82,482,764       82,101,813   Diluted   77,307,279       82,236,018       83,112,757       78,965,385       83,032,424       82,717,640     ICON plc CONSOLIDATED BALANCE SHEETS AS AT DECEMBER 31, 2025 AND DECEMBER 31, 2024 AND DECEMBER 31, 2023 (UNAUDITED)     December 31, 2025   December 31, 2024 (As Restated)   December 31, 2023 (As Restated) ASSETS (in thousands) Current assets:           Cash and cash equivalents $ 647,295     $ 538,785     $ 378,102   Available for sale investments   —       —       1,954   Accounts receivable, net of allowance for credit losses   1,474,898       1,392,764       1,764,404   Unbilled revenue   1,096,592       1,040,174       853,581   Other receivables   116,750       79,487       65,797   Prepayments and other current assets   105,316       140,435       132,105   Income taxes receivable   60,824       83,523       91,254   Total current assets $ 3,501,675     $ 3,275,168     $ 3,287,197               Non-current assets:           Property, plant and equipment, net   395,724       382,879       361,184   Goodwill   8,731,689       9,051,410       9,022,075   Intangible assets, net   3,247,118       3,559,792       3,855,865   Operating right-of-use assets   128,948       147,602       140,333   Other receivables   75,707       72,796       78,470   Income taxes receivable   —       11,395       —   Deferred tax asset   106,871       75,832       72,855   Investments in equity   82,050       57,948       46,804   Total Assets $ 16,269,782     $ 16,634,822     $ 16,864,783               LIABILITIES AND SHAREHOLDERS’ EQUITY           Current liabilities:           Accounts payable $ 192,117     $ 173,025     $ 131,584   Unearned revenue   1,550,471       1,467,671       1,566,464   Other liabilities   904,826       909,776       908,151   Income taxes payable   18,999       55,258       13,968   Current bank credit lines, loan facilities and notes   529,762       29,762       110,150   Total current liabilities $ 3,196,175     $ 2,635,492     $ 2,730,317               Non-current liabilities:           Non-current bank credit lines, loan facilities and notes, net   2,872,616       3,396,398       3,665,439   Lease liabilities   117,122       140,085       126,321   Non-current other liabilities   72,807       82,718       45,246   Non-current income taxes payable   103,251       127,544       187,706   Deferred tax liability   714,427       811,231       898,308   Commitments and contingencies   —       —       —   Total Liabilities $ 7,076,398     $ 7,193,468     $ 7,653,337               Shareholders' Equity:           Ordinary shares, par value 6 euro cents per share; 100,000,000 shares authorized,           76,567,325 shares issued and outstanding at December 31, 2025, (2024: 80,756,860 and 2023: 82,495,086)   6,305       6,586       6,699   Additional paid-in capital   7,131,956       7,020,231       6,942,669   Other undenominated capital   1,606       1,304       1,162   Accumulated other comprehensive loss   (68,534 )     (229,929 )     (143,506 ) Retained earnings   2,122,051       2,643,162       2,404,422   Total Shareholders' Equity $ 9,193,384     $ 9,441,354     $ 9,211,446   Total Liabilities and Shareholders' Equity $ 16,269,782     $ 16,634,822     $ 16,864,783     ICON plc CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2025 AND DECEMBER 31, 2024 AND DECEMBER 31, 2023 (UNAUDITED)     Year ended December 31,     2025     2024 (As Restated)   2023 (As Restated)   (in thousands) Cash flows provided by operating activities:           Net income $ 229,339     $ 739,126     $ 554,208               Adjustments to reconcile net income to net cash provided by operating activities:           Depreciation and amortization   382,996       488,500       585,950   Goodwill impairment   364,248       —       —   Impairment of non-financial assets   101,027       —       —   Impairment of operating right-of-use assets and related property, plant and equipment   3,683       15,731       8,686   Reduction in carrying value of operating right-of-use assets   36,116       39,787       41,546   Loss on equity method investments   —       —       383   Acquisition-related gain   —       —       (6,160 ) Amortization of financing costs and debt discount   5,980       23,533       16,402   Stock compensation expense   102,041       45,870       55,667   Deferred tax benefit   (128,919 )     (102,886 )     (85,388 ) Unrealized foreign exchange movements   26,464       6,911       19,706   Other non-cash items   11,333       31,900       24,332   Changes in operating assets and liabilities:           Accounts receivable   (108,213 )     332,616       (57,378 ) Unbilled revenue   (61,109 )     (192,176 )     118,328   Unearned revenue   68,516       (96,787 )     46,523   Other net assets   2,703       (45,473 )     (161,778 ) Net cash provided by operating activities   1,036,205       1,286,652       1,161,027               Cash flows used in investing activities:           Purchase of property, plant and equipment   (174,214 )     (168,060 )     (140,692 ) Purchase of subsidiary undertakings (net of cash acquired)   (2,537 )     (84,159 )     (71,766 ) Movement of available for sale investments   —       —       (241 ) Proceeds from investments in equity   9,089       2,690       —   Purchase of investments in equity   (19,871 )     (17,261 )     (13,954 ) Net cash used in investing activities   (187,533 )     (266,790 )     (226,653 )             Cash flows used in financing activities:           Debt issue costs   (750 )     (12,679 )     —   Drawdown of credit lines and loan facilities   50,000       2,317,480       370,000   Repayment of credit lines and loan facilities   (79,762 )     (2,677,763 )     (1,265,000 ) Proceeds from exercise of equity compensation   9,724       36,187       50,973   Share issue costs   (19 )     (22 )     (16 ) Repurchase of ordinary shares   (750,000 )     (499,998 )     —   Share repurchase costs   (450 )     (388 )     —   Net cash used in financing activities   (771,257 )     (837,183 )     (844,043 )             Effect of exchange rate movements on cash   31,095       (21,996 )     (997 ) Net increase in cash and cash equivalents   108,510       160,683       89,334   Cash and cash equivalents at beginning of period   538,785       378,102       288,768   Cash and cash equivalents at end of period $ 647,295     $ 538,785     $ 378,102                 ICON plc RECONCILIATION OF NON-GAAP MEASURES FOR EACH QUARTER AND TWELVE MONTHS ENDED DECEMBER 31, 2025 (UNAUDITED)     Three Months Ended   Year Ended   March 31, 2025 (As Restated)   June 30, 2025 (As Restated)   September 30, 2025 (As Restated)   December 31, 2025   December 31, 2025   (in thousands, except share and per share data)                     Adjusted EBITDA                   Net income $ 160,812     $ 203,516     $ (284,183 )   $ 149,194     $ 229,339   Income tax expense / (benefit)   20,351       (20,674 )     12,791       10,658       23,126   Net interest expense   45,807       48,097       48,482       47,995       190,381   Depreciation and amortization   95,958       97,718       99,030       90,290       382,996   Stock-based compensation expense (a)   12,294       15,433       46,191       30,612       104,530   Foreign currency losses / (gains), net (b)   18,095       24,015       (6,860 )     4,061       39,311   Restructuring (c)   39,346       42,950       —       (3,227 )     79,069   Transaction, integration related and other (d)   5,404       6,717       7,020       12,626       31,767   Fair value movement on investments in equity (f)   —       —       —       (15,108 )     (15,108 ) Goodwill impairment (g)   —       —       364,248       —       364,248   Impairment of non-financial assets (h)   —       —       101,027       —       101,027   Adjusted EBITDA $ 398,067     $ 417,772     $ 387,746     $ 327,101     $ 1,530,686                       Adjusted net income and adjusted diluted net income per Ordinary Share                   Net income $ 160,812     $ 203,516     $ (284,183 )   $ 149,194     $ 229,339   Income tax expense / (benefit)   20,351       (20,674 )     12,791       10,658       23,126   Amortization   58,946       59,057       58,688       50,529       227,220   Stock-based compensation expense (a)   12,294       15,433       46,191       30,612       104,530   Foreign currency losses / (gains), net (b)   18,095       24,015       (6,860 )     4,061       39,311   Restructuring (c)   39,346       42,950       —       (3,227 )     79,069   Transaction, integration related and other (d)   5,404       6,717       7,020       12,626       31,767   Transaction-related financing costs (e)   1,465       1,506       1,499       1,510       5,980   Fair value movement on investments in equity (f)   —       —       —       (15,108 )     (15,108 ) Goodwill impairment (g)   —       —       364,248       —       364,248   Impairment of non-financial assets (h)   —       —       101,027       —       101,027   Adjusted tax expense (i)   (51,941 )     (52,206 )     (50,771 )     (45,762 )     (200,680 ) Adjusted net income $ 264,772     $ 280,314     $ 249,650     $ 195,093     $ 989,829                       Diluted weighted average number of Ordinary Shares outstanding   80,924,355       79,547,444       78,082,459       77,307,279       78,965,385                       Adjusted diluted net income per Ordinary Share $ 3.27     $ 3.52     $ 3.20     $ 2.52     $ 12.53     ICON plc RECONCILIATION OF NON-GAAP MEASURES FOR EACH QUARTER AND TWELVE MONTHS ENDED DECEMBER 31, 2024 (UNAUDITED)     Three Months Ended   Year Ended   March 31, 2024 (As Restated)   June 30, 2024 (As Restated)   September 30, 2024 (As Restated)   December 31, 2024 (As Restated)   December 31, 2024 (As Restated)   (in thousands, except share and per share data)                     Adjusted EBITDA                   Net income $ 148,337     $ 82,776     $ 213,268     $ 294,745     $ 739,126   Income tax expense / (benefit)   24,376       14,589       38,432       (12,767 )     64,630   Net interest expense   69,735       59,603       50,869       48,421       228,628   Depreciation and amortization   149,181     149,635     93,029     96,655       488,500   Stock-based compensation expense (a)   13,181       14,964       13,038       4,687       45,870   Foreign currency (gains) / losses, net (b)   (10,814 )     3,340       19,434       (30,045 )     (18,085 ) Restructuring (c)   —       45,789       —       46,334       92,123   Transaction and integration related (d)   6,991       6,820       7,856       7,907       29,574   Adjusted EBITDA $ 400,987     $ 377,516     $ 435,926     $ 455,937     $ 1,670,366                       Adjusted net income and adjusted diluted net income per Ordinary Share                   Net income $ 148,337     $ 82,776     $ 213,268     $ 294,745     $ 739,126   Income tax expense / (benefit)   24,376       14,589       38,432       (12,767 )     64,630   Amortization   116,498       116,489       58,026       59,278       350,291   Stock-based compensation expense (a)   13,181       14,964       13,038       4,687       45,870   Foreign currency (gains) / losses, net (b)   (10,814 )     3,340       19,434       (30,045 )     (18,085 ) Restructuring (c)   —       45,789       —       46,334       92,123   Transaction and integration related (d)   6,991       6,820       7,856       7,907       29,574   Transaction-related financing costs (e)   3,907       16,697       1,462       1,467       23,533   Adjusted tax expense (i)   (52,933 )     (52,756 )     (56,946 )     (54,254 )     (216,889 ) Adjusted net income $ 249,543     $ 248,708     $ 294,570     $ 317,352     $ 1,110,173                       Diluted weighted average number of Ordinary Shares outstanding   83,249,303       83,360,841       83,445,827       82,236,018       83,032,424                       Adjusted diluted net income per Ordinary Share $ 3.00     $ 2.98     $ 3.53     $ 3.86     $ 13.37     ICON plc RECONCILIATION OF NON-GAAP MEASURES FOR EACH QUARTER AND TWELVE MONTHS ENDED DECEMBER 31, 2023 (UNAUDITED)     Three Months Ended   Year Ended   March 31, 2023 (As Restated)   June 30, 2023 (As Restated)   September 30, 2023 (As Restated)   December 31, 2023 (As Restated)   December 31, 2023 (As Restated)   (in thousands, except share and per share data)                     Adjusted EBITDA                   Net income $ 108,877     $ 108,045     $ 153,901     $ 183,385     $ 554,208   Share of losses from equity method investments   383       —       —       —       383   Income tax expense / (benefit)   12,904       8,266       16,384       (19,166 )     18,388   Net interest expense   85,479       84,257       82,635       79,314       331,685   Depreciation and amortization   145,126     145,059     146,032     149,733       585,950   Stock-based compensation expense (a)   14,759       16,598       16,465       7,845       55,667   Foreign currency losses / (gains), net (b)   1,338       903       (4,706 )     15,381       12,916   Oncacare (gain) (j)   —       (6,160 )     —       —       (6,160 ) Restructuring (c)   9,729       35,661       —       —       45,390   Transaction and integration related (d)   11,382       12,701       10,433       9,660       44,176   Adjusted EBITDA $ 389,977     $ 405,330     $ 421,144     $ 426,152     $ 1,642,603                       Adjusted net income and adjusted diluted net income per Ordinary Share                   Net income $ 108,877     $ 108,045     $ 153,901     $ 183,385     $ 554,208   Income tax expense / (benefit)   12,904       8,266       16,384       (19,166 )     18,388   Amortization   114,678       114,617       114,573       115,986       459,854   Stock-based compensation expense (a)   14,759       16,598       16,465       7,845       55,667   Foreign currency losses / (gains), net (b)   1,338       903       (4,706 )     15,381       12,916   Restructuring (c)   9,729       35,661       —       —       45,390   Oncacare (gain) (j)   —       (6,160 )     —       —       (6,160 ) Transaction and integration related (d)   11,382       12,701       10,433       9,660       44,176   Transaction-related financing costs (e)   4,498       3,401       4,587       3,916       16,402   Adjusted tax expense (i)   (45,897 )     (44,693 )     (47,369 )     (62,450 )     (200,409 ) Adjusted net income $ 232,268     $ 249,339     $ 264,268     $ 254,557     $ 1,000,432                       Diluted weighted average number of Ordinary Shares outstanding   82,605,659       82,627,933       82,972,888       83,112,757       82,717,640                       Adjusted diluted net income per Ordinary Share $ 2.81     $ 3.02     $ 3.18     $ 3.06     $ 12.09   (a) Stock-based compensation expense represents the amount of expense related to the Company’s equity compensation programs (inclusive of employer related taxes). (b) Foreign currency (gains) / losses, net relates to losses or gains that arise in connection with the revaluation, or settlement, of non-US dollar denominated assets and liabilities. We exclude these losses and gains from adjusted EBITDA and adjusted net income because fluctuations from period-to-period do not necessarily correspond to changes in our operating results. (c) Restructuring relates to charges incurred in connection with the Company's realignments of its workforce, with the elimination of redundant positions as well as reviewing its global office footprint and optimizing its locations to best fit the requirements of the Company. (d) Transaction, integration related and other costs include expenses associated with our acquisitions and any other costs incurred directly related to the integration of these acquisitions. Further, costs incurred in quarter four 2025 relating to the Investigation, including out of scope audit fees resulting from the impact of the investigation, and in defense of the Putative Class Action are classified within this category. (e) Transaction-related financing costs includes costs incurred in connection with changes to our long-term debt and amortization of financing fees. We exclude these costs from adjusted EBITDA and adjusted net income because they result from financing decisions rather than from decisions made related to our ongoing operations. (f) Fair value movement on investments in equity. We exclude these movements from adjusted EBITDA and adjusted net income because fluctuations from period-to-period do not necessarily correspond to changes in our operating results. (g) Goodwill impairment relates to an impairment of goodwill allocated to the Company's Data Solutions reporting unit. (h) Impairment of non-financial assets relates to an impairment of the carrying amount of the property, plant and equipment and intangible assets of the Company's Data Solutions reporting unit. (i) Represents the tax effect of adjusted pre-tax income at our estimated effective tax rate. (j) On April 20, 2023, the Company completed the purchase of the majority investor’s 51% majority voting share capital of Oncacare Limited (“Oncacare”). This gave rise to an acquisition-related gain of $6.2 million. This gain was excluded from adjusted EBITDA and adjusted net income.   View source version on businesswire.com: https://www.businesswire.com/news/home/20260527795837/en/ Investor Relations +1 888 381 7923
Nigel Clerkin Chief Financial Officer +353 1 291 2000
Kate Haven Vice President Investor Relations +1 888 381 7923
All at ICON
http://www.iconplc.com Original: ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee Investigation

ICON Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call and Acknowledges Receipt of Deficiency Notice from NasdaqMay 26, 2026 4:05 PM
Business Wire ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today announced that it will release financial results for the fourth quarter and full year 2025 results after the market closes on Wednesday, May 27, 2026. The Company will hold a conference call and webcast to discuss its financial results and performance on Thursday, May 28, 2026 at 8:00am ET. The Company also announced that, as expected, as a consequence of not yet having filed its Annual Report on Form 20-F for the year ended December 31, 2025 (the “Form 20-F”), the Company has received a written notice from Nasdaq indicating that it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires timely filing of all required periodic financial reports with the U.S. Securities and Exchange Commission. The notice has no immediate impact on the listing or trading of the Company’s securities. Nasdaq has provided the Company with 60 calendar days from the date of the notice to submit a plan to regain compliance. The Company expects to regain compliance upon filing the Form 20-F, which it currently anticipates completing in advance of the conference call. Other Information Certain statements contained herein are forward-looking statements. All statements other than statements of historical fact are forward-looking. Examples of forward-looking statements include, but are not limited to, statements regarding the finalization of and timing of filing the Form 20-F and the Company’s ability to regain compliance with the Listing Rule. You can identify many forward-looking statements by words such as “aims,” “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “focused,” “guidance,” “intends,” “may,” “opportunities,” “plans,” “position,” “potential,” “predicts,” “projects,” “proposed,” “seeks,” “should,” “will,” “would” and other similar expressions and the negatives of such expressions. However, not all forward-looking statements contain these words. These statements are based on management's current expectations and information currently available. Actual results may differ materially from those stated or implied by forward-looking statements due to risks and uncertainties associated with the Company's management and operations, and forward-looking statements are not guarantees of future performance. Such risks and uncertainties include, but are not limited to: risks related to the ability of the Company to finalize the Form 20-F and complete the external audit; delays due to unforeseen additional work needed to complete the filing of the Form 20-F; risks related to Company’s plan to regain compliance with the Listing Rule; and other factors, including those factors described in the section entitled “Risk Factors” of the Company’s Annual Report on Form 20-F most recently filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made and the Company does not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise, except to the extent required by law. About ICON plc ICON plc is a world-leading clinical research organization. Offering deep operational and medical expertise we accelerate innovation, driving emerging therapies forward to improve patient outcomes. From molecule to medicine, we deliver integrated consulting, clinical development, commercialization and post-marketing solutions to pharmaceutical, biotechnology, medical device, government and public health organizations worldwide. With headquarters in Dublin, Ireland, ICON employed approximately 40,100 employees in 97 locations in 55 countries as of December 31, 2025. For further information about ICON, visit: www.iconplc.com. ICON/ICLR-F View source version on businesswire.com: https://www.businesswire.com/news/home/20260526404425/en/ Investor Relations +1 888 381 7923
Nigel Clerkin Chief Financial Officer +353 1 291 2000
Kate Haven Vice President Investor Relations +1 888 381 7923
All at ICON Original: ICON Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call and Acknowledges Receipt of Deficiency Notice from Nasdaq

ICON plc Provides Update on Timing of Fourth Quarter and Full Year 2025 Earnings Results and Investigation into Accounting PracticesFebruary 12, 2026 6:00 AM
Business Wire
Investigation’s preliminary indications are that 2023 and 2024 revenue may have been overstated by less than 2% for each fiscal year


ICON plc, (NASDAQ: ICLR) today announced that it intends to release its fourth quarter and full year 2025 earnings results on or prior to April 30, 2026. The Company also announced an ongoing internal investigation initiated by the Audit Committee of the Board of Directors in late October 2025 into certain of the Company’s accounting practices and controls, following concerns reported to the Audit Committee through Company management. Outside legal counsel is conducting the investigation with the support of forensic and technical accounting firms.


The investigation primarily focuses on revenue recognition in fiscal years 2023 through 2025. The Company is in the process of evaluating the design and operation of certain internal controls over financial reporting and expects to report one or more material weaknesses as a result. While the investigation is continuing, at this time, preliminary indications are that the Company’s revenue in 2023 and 2024 may have been overstated by less than two percent for each fiscal year. Due to the ongoing investigation, including a delay of normal quarter and year-end reporting processes, the Company is not yet able to communicate its 2025 financial performance and is withdrawing its previously issued 2025 full year financial guidance.


The investigation has not identified any impact to customers stemming from the practices under review. ICON remains fully focused on its mission to partner with customers to expedite the development of novel therapeutics for patients globally.


ICON’s Chair, Mr. Ciaran Murray said, “The ICON Board of Directors is committed to transparency, accountability and strong governance. The Board of Directors and I have full faith in ICON’s executive team and their ability to implement the changes needed as a result of the investigation and execute our strategy for the years ahead.”


ICON’s CEO, Mr. Barry Balfe commented, “ICON is a strong business underpinned by a longstanding commitment to quality, integrity and transparency. In response to the current investigation, we are implementing a series of corrective actions to enhance our internal controls over financial reporting. I look forward to reporting our 2025 results and to providing commentary on the broader market as we continue to execute on our commercial strategy. I am proud of our teams and the great work they do for our customers to deliver new treatments for patients.”


Other Information


This press release contains forward-looking statements, including statements about our financial guidance and the ongoing independent investigation by the Audit Committee of the Board of the Directors. These statements are based on management's current expectations and information currently available. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the timing and completion of the Company’s reporting of its fourth quarter and full year 2025 results, the timing and completion of the filing of the Company’s Form 20-F for the year ended December 31, 2025, the evaluation of material weaknesses in internal control over financial reporting, the timing and completion of the audit committee investigation and the results thereof, the timing of the review by, and the conclusions of, the Company’s independent registered public accounting firm regarding the audit committee’s internal review and the Company’s financial statements, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, the impact of this announcement on the price of the Company’s common stock and the Company’s relationships with investors, employees, suppliers, wholesalers, lenders and other parties, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected", “intend”, “indication” and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its latest Annual Report on Form 20-F, Form 6-Ks and certain other reports, which are available on the SEC's website at http://www.sec.gov.


About ICON plc


ICON plc is a world-leading clinical research organisation. Offering deep operational and medical expertise we accelerate innovation, driving emerging therapies forward to improve patient outcomes. From molecule to medicine, we deliver integrated consulting, clinical development, commercialisation and post-marketing solutions to pharmaceutical, biotechnology, medical device, government and public health organisations worldwide. With headquarters in Dublin, Ireland, ICON employed approximately 40,100 employees in 97 locations in 55 countries as of December 31, 2025. For further information about ICON, visit: www.iconplc.com.


ICON/ICLR-F

View source version on businesswire.com: https://www.businesswire.com/news/home/20260212455719/en/
Investor Relations +1 888 381 7923

Nigel Clerkin Chief Financial Officer +353 1 291 2000

Kate Haven Vice President Investor Relations +1 888 381 7923

All at ICON


Original: ICON plc Provides Update on Timing of Fourth Quarter and Full Year 2025 Earnings Results and Investigation into Accounting Practices

ICON’s Accellacare Site Network Expands Oncology Research Capabilities With New Cancer Institute PartnershipJanuary 27, 2026 12:15 PM
Business Wire
ICON plc (NASDAQ: ICLR) today announced a significant expansion of oncology research capabilities within its Accellacare Site Network through the opening of the Brian Moran Cancer Institute at Duly Health and Care in Illinois.


The new institute strengthens Accellacare’s ability to support oncology clinical trials and broaden access to innovative cancer treatments for patients. The Brian Moran Cancer Institute includes:


? 14 medical oncologists

? Three radiation oncologists

? Nine fellowship-trained surgical specialists in urologic oncology, breast surgery, colorectal surgery, endocrine surgery, and general surgical oncology


This development builds on Accellacare’s existing oncology expertise at the McFarland Clinic in Ames, Iowa, and reflects ICON’s commitment to addressing patient recruitment for oncology trials, which is one of the most pressing challenges in clinical development.


Brian Mallon EVP, Sites & Patient Solutions, ICON, commented:


“Our partnership with the Brian Moran Cancer Institute marks a major step forward in our mission to accelerate oncology research and improve patient access to new therapies. Through our collaboration, we are expanding our investigator base and developing a flagship oncology site, creating more opportunities for sponsors and patients alike. Together we’re working to bring hope to people affected by cancer.”


About Accellacare


Accellacare Site Network operates 50 sites across multiple countries with a team of over 300 dedicated research professionals and over 150 Principal Investigators. In addition to oncology, the Accellacare team works in a wide range of therapeutic areas, from vaccines and women's health to obesity, CNS and respiratory studies. Learn more at www.accellacare.com.


About ICON plc


ICON plc is a world-leading clinical research organisation. Offering deep operational and medical expertise we accelerate innovation, driving emerging therapies forward to improve patient outcomes. From molecule to medicine, we deliver integrated consulting, clinical development, commercialisation and post-marketing solutions to pharmaceutical, biotechnology, medical device, government and public health organisations worldwide. With headquarters in Dublin, Ireland, ICON employed approximately 39,800 employees in 95 locations in 55 countries as of 30 September, 2025. For further information about ICON, visit: www.iconplc.com.


About the Brian Moran Cancer Institute


The Brian Moran Cancer Institute at Duly Health and Care brings leading-edge oncology care to patients throughout the Chicago suburbs and beyond. BMCI provides access to innovative cancer treatments, numerous clinical trials, precision diagnostics, and integrated supportive services?—?all within one coordinated system.


DuPage Medical Group, Ltd. dba Brian Moran Cancer Institute


About Duly Health and Care


The Duly Health and Care brand consists of some of the largest independent, multi-specialty, physician-directed medical groups in the United States, with more than 1,000 primary care and specialty care providers and over 6,000 team members across more than 150 locations. The Duly Health and Care brand includes three medical groups?—?DuPage Medical Group Ltd., Quincy Medical Group, and The South Bend Clinic LLC. Duly is deeply committed to caring for patients in traditional and value-based care arrangements, ensuring a focus on quality, efficiency, and enhanced patient experiences throughout the US Midwest.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260127530337/en/
Media contacts

Lisa Henry (GMT time zone)

Weber Shandwick (PR adviser)

+447785 458203

lhenry@webershandwick.com


ICON Press Office

iconnews@webershandwick.com


Original: ICON’s Accellacare Site Network Expands Oncology Research Capabilities With New Cancer Institute Partnership

Lot going on here ICLR WOOHOOOOOOOOOOOOOOO $400 TARGET PRICE

$ICLR great article Icon Plc Nasdaq Iclr Short Squeeze

ICON is scheduled to report earnings on Thursday and the stock is currently trading near its 52-week high. However, finbox.io fair value data implies that shares are still 18% undervalued:

Six Healthcare Stocks with Nice Upside Potential

ICLR bullish 76.12

bull flag

SEC suspension cancelled.

ICLR: SEC Admin Proceeding still active:

http://www.sec.gov/litigation/admin/2014/34-73406.pdf

Excerpts:
The Securities and Exchange Commission (“Commission”) deems it necessary and appropriate for the protection of investors that public administrative proceedings be, and hereby are, instituted pursuant to Section 12(j) of the Securities Exchange Act of 1934 (“Exchange Act”) against Respondents 21st Century Telesis II, Inc., Agemark Corp., Alnilam Corp., American Centrality Group, Inc., China Feicui Guodian Group Ltd., and Icon Public Ltd. Co


6. Icon Public Ltd. Co. (CIK No. 1060373) is an Irish company located in Dublin, Ireland with a class of securities registered with the Commission pursuant to Exchange Act Section 12(g). Icon Public is delinquent in its periodic filings with the Commission, having not filed any periodic reports since it filed a Form 20-F for the period ended May 31, 2002, which reported a net loss of $87,939 for the prior three months. As of October 16, 2014, the company’s stock (symbol “ICLR”) was quoted on Nasdaq, had four market makers, and was eligible for the “piggyback” exception of Exchange Act Rule 15c2-11(f)(3).

B. DELINQUENT PERIODIC FILINGS

7. As discussed in more detail above, all of the Respondents are delinquent in their periodic filings with the Commission, have repeatedly failed to meet their obligations to file timely periodic reports, and failed to heed delinquency letters sent to them by the Division of Corporation Finance requesting compliance with their periodic filing obligations or, through their failure to maintain a valid address on file with the Commission as required by Commission rules, did not receive such letters.

8. Exchange Act Section 13(a) and the rules promulgated thereunder require issuers of securities registered pursuant to Exchange Act Section 12 to file with the Commission current and accurate information in periodic reports, even if the registration is voluntary under Section 12(g). Specifically, Rule 13a-1 requires issuers to file annual reports, and Rule 13a-13 requires domestic issuers to file quarterly reports.

9. As a result of the foregoing, Respondents failed to comply with Exchange Act Section 13(a) and Rules 13a-1 and/or 13a-13 thereunder.

In view of the allegations made by the Division of Enforcement, the Commission deems it necessary and appropriate for the protection of investors that public administrative proceedings be instituted to determine:

A. Whether the allegations contained in Section II hereof are true and, in connection therewith, to afford the Respondents an opportunity to establish any defenses to such allegations; and,

B. Whether it is necessary and appropriate for the protection of investors to suspend for a period not exceeding twelve months, or revoke the registration of each class of securities registered pursuant to Section 12 of the Exchange Act of the Respondents identified in Section II hereof, and any successor under Exchange Act Rules 12b-2 or 12g-3, and any new corporate names of any Respondents

IT IS HEREBY ORDERED that a public hearing for the purpose of taking
evidence on the questions set forth in Section III hereof shall be convened at a time and place to be fixed, and before an Administrative Law Judge to be designated by further order as provided by Rule 110 of the Commission’s Rules of Practice [17 C.F.R. § 201.110].

IT IS HEREBY FURTHER ORDERED that Respondents shall file an Answer to
the allegations contained in this Order within ten (10) days after service of this Order, as provided by Rule 220(b) of the Commission’s Rules of Practice [17 C.F.R. § 201.220(b)].

If Respondents fail to file the directed Answers, or fail to appear at a hearing after being duly notified, the Respondents, and any successor under Exchange Act Rules 12b-2 or 12g-3, and any new corporate names of any Respondents, may be deemed in default and the proceedings may be determined against them upon consideration of this Order, the allegations of which may be deemed to be true as provided by Rules 155(a), 220(f), 221(f), and 310 of the Commission’s Rules of Practice [17 C.F.R. §§ 201.155(a), 201.220(f), 201.221(f), and 201.310].

This Order shall be served forthwith upon Respondents personally or by certified, registered, or Express Mail, or by other means permitted by the Commission Rules of Practice.

IT IS FURTHER ORDERED that the Administrative Law Judge shall issue an
initial decision no later than 120 days from the date of service of this Order, pursuant to Rule 360(a)(2) of the Commission’s Rules of Practice [17 C.F.R. §201.360(a)(2)].

In the absence of an appropriate waiver, no officer or employee of the
Commission engaged in the performance of investigative or prosecuting functions in this or any factually related proceeding will be permitted to participate or advise in the decision of this matter, except as witness or counsel in proceedings held pursuant to notice. Since this proceeding is not “rule making” within the meaning of Section 551 of the Administrative Procedure Act, it is not deemed subject to the provisions of Section 553 delaying the effective date of any final Commission action.

By the Commission.
Brent J. Fields
Secretary

ICLR SEC Suspension cancelled.

http://www.sec.gov/litigation/suspensions.shtml

ICLR: SEC Suspension:

http://www.sec.gov/litigation/suspensions/2014/34-73405.pdf

Order:

http://www.sec.gov/litigation/suspensions/2014/34-73405-o.pdf

Admin Proceeding:

http://www.sec.gov/litigation/admin/2014/34-73406.pdf

$ICLR DD Notes ~ http://www.ddnotesmaker.com/ICLR

bullish
ascending triangle breakout

$ICLR recent news/filings

## source: finance.yahoo.com

Wed, 10 Sep 2014 12:52:00 GMT ~ Medidata and ICON Join Forces to Bring New Productivity to Capturing Patient Voice in Clinical Trials

[Business Wire] - Medidata , the leading global provider of cloud-based solutions for clinical research in life sciences, and ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced a joint initiative designed to bring new efficiencies to the administration of electronic patient-reported outcomes in clinical trials.

read full: http://finance.yahoo.com/news/medidata-icon-join-forces-bring-125200191.html
*********************************************************

Wed, 03 Sep 2014 18:30:00 GMT ~ AMBS: Amarantus Investor Call Highlights Clinical And Commercial Milestones


read full: http://finance.yahoo.com/news/ambs-amarantus-investor-call-highlights-183000366.html
*********************************************************

Tue, 26 Aug 2014 11:06:34 GMT ~ iKang Healthcare Group, Inc. (KANG) Jumps: Stock Surges 10.1%


read full: http://finance.yahoo.com/news/ikang-healthcare-group-inc-kang-110634230.html
*********************************************************

Mon, 25 Aug 2014 11:22:02 GMT ~ Is ICON Public Limited (ICLR) Stock a Solid Choice Right Now?


read full: http://finance.yahoo.com/news/icon-public-limited-iclr-stock-112202155.html
*********************************************************

Sat, 23 Aug 2014 11:00:00 GMT ~ A Shift in Health-Care M&A Activity


read full: http://news.morningstar.com/articlenet/article.aspx?id=662615&SR=Yahoo
*********************************************************


$ICLR charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$ICLR company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ICLR/company-info
Ticker: $ICLR
OTC Market Place: Not Available
CIK code: 0001060955
Company name: ICON plc
Incorporated In: Ireland


$ICLR share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$ICLR extra dd links

Company name: ICON plc
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ICLR+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ICLR+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ICLR+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ICLR/news - http://finance.yahoo.com/q/h?s=ICLR+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ICLR/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ICLR/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ICLR+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ICLR
DTCC (dtcc.com): http://search2.dtcc.com/?q=ICON+plc&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=ICON+plc
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=ICON+plc&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ICLR
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001060955&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ICLR/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ICLR/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ICLR&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ICLR
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ICLR/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ICLR+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ICLR+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ICLR
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ICLR
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ICLR+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ICLR/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ICLR+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ICLR.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ICLR
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ICLR/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ICLR
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ICLR
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ICLR:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ICLR
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ICLR



$ICLR DD Notes ~ http://www.ddnotesmaker.com/ICLR

News Story
Credit Suisse Starts ICON plc (ICLR) at Outperform
Print
6:44 AM 3/27/2014 - StreetInsider

Credit Suisse initiated coverage on ICON plc (NASDAQ: ICLR) with anOutperform rating and a price target of $55.00.

http://seekingalpha.com/article/1575362-icon-plc-ordinary-shares-iclr-management-discusses-q2-2013-results-earnings-call-transcript

http://seekingalpha.com/article/1372991-icon-public-limited-management-discusses-q1-2013-results-earnings-call-transcript?

6:41 AM ICON plc (ICLR): Q1 EPS of $0.36 beats by $0.02. Revenue of $317M (+26% Y/Y) beats by $14.71M

http://www.marketintelligencecenter.com/articles/269311

ICON Plc (ICLR) Market Cap: $1.96 billion
ICLR is a Contract Research Organization. These organizations are essential to the pharmaceutical industry as they handle the time consuming and messy process of managing the clinical trials necessary for the approval of new medicines. The largest player in the industry is privately held Quintiles, but among the public companies, ICLR appears best positioned for a long, steady climb. ICLR has demonstrated robust growth, with revenue rising from $297 million in 2003 to $1,115 million in 2012, an increase of 275%. ICLR has a global presence and offers laboratory services as well, meaning that they can do just about everything for their clients except create new molecules. We see ICLR as a buy and hold opportunity.

ICON Announces Appointment of Professor William Hall to Board of Directors


12:30 PM 2/21/2013 - Business Wire

DUBLIN--(BUSINESS WIRE)--Feb. 21, 2013-- ICONplc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Professor William Hall as a non-executive director.

A renowned expert in infectious diseases and virology, Professor Hall is Chair of Medical Microbiology and Director of the Centre for Research in Infectious Diseases at University College Dublin’s (UCD) School of Medicine and Medical Science. He is also a director of UCD’s National Virus Reference Laboratory and is a consultant microbiologist at St. Vincent’s University Hospital Dublin. Professor Hall also serves as a consultant to the Minister of Heath and Children in the Republic of Ireland, providing input on a number of topics including influenza pandemic preparedness and bioterrorism.

Prior to his tenure at UCD, Professor Hall was Professor and Head of the Laboratory of Medical Virology, Senior Physician and Director of the Clinical Research Centre at the Rockefeller University in New York. He has also served as an Assistant and Associate Professor of Medicine at Cornell University.

Professor Hall is a board member of The Atlantic Philanthropies and is a co-founder of the Global Virus Network.

“We are delighted to welcome Professor Hall to the ICON Board,” commented Chairman, Mr. Thomas Lynch. “His knowledge and expertise in virology and infectious diseases, coupled with his international research collaborations in these fields will complement the strengths and talents of our existing board members.”

The information contained in this release is as of 21stFebruary 2013. The statements made in this press release may contain forward-looking statements that involve a number of risks and uncertainties. A description of risks and uncertainties relating to ICON and its business can be found in ICON’s Annual Report for the fiscal year ended December 31, 2011 and in the forms filed with the US Securities and Exchange Commission, including the Forms 20-F, F-1, S-8 and F-3. ICON disclaims any intent or obligation to update these forward-looking statements.

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 79 locations in 37 countries and has approximately 10,045 employees. Further information is available at www.iconplc.com.

Source: ICON plc

ICON/ICLR-F




Source: ICON plc

ICON plc
Investor Relations 1-888-381-7923
or
Brendan Brennan Chief Financial Officer
+ 353 –1-291-2000
or
Sam Farthing VP Investor Relations
+ 353 –1-291-2000
or
Simon Holmes EVP Investor Relations and Corporate Development
+ 353 –1-291-2000

Jeffries raises P/T to $33.50, Raymond James raises it to STRONG BUY

ICON To Acquire Clinical Trial Services Division of Cross Country Healthcare Inc

ICON To Acquire Clinical Trial Services Division of Cross Country Healthcare Inc.

Acquisition Expands ICON’s Global Resourcing, FSP and Safety Capabilities

Dublin, Ireland, 4th February, 2013 – ICON plc, (NASDAQ: ICLR; ISIN: IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has agreed, subject to certain closing conditions, to acquire the Clinical Trial Services Division of Cross Country Healthcare, Inc. (NASDAQ:CCRN), for a cash consideration of $52 million, plus an earn-out of up to $3.75 million related to certain performance-based milestones. The transaction is expected to close within the next 30 days.

Cross Country Healthcare’s Clinical Trial Services Division includes leading US resourcing providers, ClinForce and Assent Consulting, whose services include contract staffing, permanent placement and functional service provision. The division also includes AKOS, a leading US and EU provider of pharmacovigilance and drug safety services. ClinForce and Assent will be combined with ICON’s FSP division, DOCS, creating a leader in global resourcing and FSP, while AKOS will enhance the services offered by ICON’s medical and safety services team.

Commenting on the acquisition, Ciaran Murray, CEO at ICON plc, said: “The demand for flexible resourcing solutions continues to grow as biopharma companies employ a range of outsourcing models to meet their development goals more efficiently. The ClinForce and Assent businesses will significantly expand our resourcing and FSP capabilities in the US and, when combined with DOCS strong European footprint and growing emerging markets presence, gives us the ability to deliver truly global resourcing solutions. Additionally, AKOS enhances our expertise in the areas of pharmacovigilance and drug safety consulting, which are increasingly important capabilities required by our clients.”

This release contains, and our officers and representatives may from time to time make, "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "strategy" and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, strategic actions, including our success in integrating ClinForce, Assent Consulting and AKOS; general economic and financial conditions; the extent to which we are successful in implementing our strategy, gaining new, long-term relationships with customers and retaining existing ones; the risk of competition on our industry; developments and changes in laws and regulations; and such other factors as discussed in Part I, Item 3 "Risk Factors" in our Form 20-F for the fiscal year ended December 31, 2011. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has approximately 9,430 employees, operating from 82 locations in 40 countries.

Further information is available at www.iconplc.com

About Cross Country Healthcare
Cross Country Healthcare, Inc. is a leader in healthcare staffing with a primary focus on providing nurse and allied and physician (locum tenens) staffing services and workforce solutions to the healthcare market. The Company believes it is one of the top two providers of nurse and allied staffing services, one of the top four providers of temporary physician staffing services, and one of the top five providers of retained physician and healthcare executive search services. The Company also is a leading provider of education and training programs specifically for the healthcare marketplace. On a company-wide basis, Cross Country Healthcare has approximately 4,000 contracts with hospitals and healthcare facilities, and other healthcare organizations to provide our staffing services and workforce solutions. Copies of this and other news releases as well as additional information about Cross Country Healthcare can be obtained online at www.crosscountryhealthcare.com. Shareholders and prospective investors can also register to automatically receive the Company's press releases, SEC filings and other notices by e-mail.

Contact Details
ICON
Brendan Brennan
Chief Financial Officer
+ 353-1-291-2000
or
Sam Farthing
VP Investor Relations
+ 353-1-291-2000
All at ICON.

Cross Country Healthcare Completes Sale of Its Clinical Trial Services Business

Today : Tuesday 19 February 2013
Click Here for more Icon Plc - Ordinary Shares (MM) Charts.

Cross Country Healthcare, Inc. (Nasdaq: CCRN) announced today it has completed the previously announced sale of its clinical trial services business to ICON plc (NASDAQ: ICLR) for $52 million, plus an earn-out of up to $3.75 million related to certain performance-based milestones. Cross Country Healthcare used a portion of the net proceeds from this transaction to repay all $29.3 million of its outstanding bank debt.

As a result of this sale, Cross Country Healthcare’s clinical trial services business segment will become discontinued operations and will be reported as such on its financial statements for all applicable periods presented in the Company’s upcoming financial reporting for the fourth quarter and year ended December 31, 2012.

“Our divestiture of this business was based on an extensive review of our operations and the changing landscape in the pharmaceutical R&D outsourcing industry. Having successfully completed this transaction, we will narrow our focus and concentrate our resources on our core nurse and allied staffing and our physician staffing businesses, which pro forma would represent about 90% of our consolidated revenue,” said Joseph A. Boshart, President and Chief Executive Officer of Cross Country Healthcare, Inc. “I also want to wish our outstanding clinical trial service team much success in the future,” added Mr. Boshart.

About Cross Country Healthcare

Cross Country Healthcare, Inc. is a leader in healthcare staffing with a primary focus on providing nurse and allied and physician (locum tenens) staffing services and workforce solutions to the healthcare market. The Company believes it is one of the top two providers of nurse and allied staffing services, one of the top four providers of temporary physician staffing services, and one of the top five providers of retained physician and healthcare executive search services. The Company also is a leading provider of education and training programs specifically for the healthcare marketplace. On a company-wide basis, Cross Country Healthcare has approximately 4,000 contracts with hospitals and healthcare facilities, and other healthcare organizations to provide our staffing services and workforce solutions. Copies of this and other news releases as well as additional information about Cross Country Healthcare can be obtained online at www.crosscountryhealthcare.com. Shareholders and prospective investors can also register to automatically receive the Company's press releases, SEC filings and other notices by e-mail.

About ICON plc

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently operates from 82 locations in 40 countries and has approximately 9,500 employees. Further information is available at www.iconplc.com.

In addition to historical information, this press release contains statements relating to our future results (including certain projections and business trends) that are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and are subject to the “safe harbor” created by those sections. Forward-looking statements consist of statements that are predictive in nature, depend upon or refer to future events. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “estimates”, “suggests”, “appears”, “seeks”, “will” and variations of such words and similar expressions intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results and performance to be materially different from any future results or performance expressed or implied by these forward-looking statements. These factors include, without limitation, the following: our ability to attract and retain qualified nurses, physicians and other healthcare personnel, costs and availability of short-term housing for our travel nurses and physicians, demand for the healthcare services we provide, both nationally and in the regions in which we operate, the functioning of our information systems, the effect of existing or future government regulation and federal and state legislative and enforcement initiatives on our business, our clients’ ability to pay us for our services, our ability to successfully implement our acquisition and development strategies, the effect of liabilities and other claims asserted against us, the effect of competition in the markets we serve, our ability to successfully defend the Company, its subsidiaries, and its officers and directors on the merits of any lawsuit or determine its potential liability, if any, and other factors set forth in Item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011, and our other Securities and Exchange Commission filings made during 2012.

Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results and readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s opinions only as of the date of this press release. There can be no assurance that (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factors’ likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct or (iv) our strategy, which is based in part on this analysis, will be successful. The Company undertakes no obligation to update or revise forward-looking statements. All references to “we,” “us,” “our,” or “Cross Country” in this press release mean Cross Country Healthcare, Inc., its subsidiaries and affiliates.

ICON Reports Fourth Quarter 2012 Revenue of $300 Million, up 24% year on year, EPS of 34c and Full Year revenue of $1.12 billion, EPS of $1.00.

Highlights — Fourth Quarter and Full year ended December 31 2012.

Quarter 4 net revenue increased 24% year on year to $300 million. Full Year 2012 net revenue increased 18% to $1.12 billion.
Quarter 4 operating income was $24.4 million or 8.1% of revenue. Full Year 2012 operating income before non- recurring charges was $73.7 million or 6.6% of revenue.
Earnings per share for Quarter 4 were $0.34. EPS for the full year 2012 before non-recurring charges was $1.00.
Quarter 4 net business awards were $378 million, a book to bill of 1.26. Full Year net new business awards were $1.6 billion, a book to bill of 1.4.
Backlog increased 20% year on year to $2.8 billion.
Guidance increased to reflect the acquisition of the clinical trial service division of Cross Country Healthcare, Inc. to revenue in the range of $1,258 — $1,292 million and EPS in the range of $1.44 — $1.60.

DUBLIN--(BUSINESS WIRE)-- ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the full year and fourth quarter ended December 31, 2012.

For the fourth quarter net revenue grew 24% year on year to $300 million. Operating income was $24.4 million compared to $6.6 million in the same quarter last year. Operating margin was 8.1% of revenue, compared to 2.7% of revenue for the same quarter last year.

Net income was $20.7 million compared with $4.1 million last year or $0.34 per share compared to $0.07 in the same quarter last year.

For the full year revenue grew 18% to $1.12 billion. Operating income before restructuring and other items was $73.7 million compared to $39.3 million last year. Operating margin for the full year 2012 was 6.6% of revenue compared with 4.2% of revenue in 2011.

On a US GAAP basis, income from operations was $68.0 million or 6.1% compared with $29.4 million or 3.1% in the prior year.

For the full year net income before restructuring and other items was $60.4 million, compared to $31.5 million last year and net margin was 5.4% of revenue, compared with 3.3% in 2011.

EPS before restructuring and other items for 2012 was $1.00 per share compared with $0.52 in 2011.

On a US GAAP basis net income was $55.4 million, compared to $22.8 million last year. Net margin for the full year 2012 was 5.0% of revenue, up from 2.4% in 2011. EPS on a US GAAP basis for 2012 was $0.92 per share compared with $0.37 in 2011.

Days sales outstanding, comprising accounts receivable and unbilled revenue less payments on account were 40 days at December 31, 2012 compared with 47 days at December 31, 2011.

For the quarter ended December 31, 2012, cash provided by operating activities was $12.0 million and capital expenditure was $8.4 million. For the full year 2012 cash flow from operating activities was $113.4 million and capital expenditure was $30.8 million. In addition $69.9 million was invested on acquisitions and $15.8 million was expended on a stock repurchase programme. As a result the company's net cash amounted to $190 million at December 31, 2012 compared to $174 million of net cash at December 31, 2011.

On the 15th of February we completed the acquisition of the clinical trial service division of Cross Country Healthcare, Inc. This will be combined with our DOCS group to create a global leader in resourcing. Consequently we have increased our full year guidance to revenue in the range of $1,258- $1,292 and EPS in the range of $1.44 - $1.60.

CEO Ciaran Murray commented, "In 2012 we saw the validation of our investment strategy as we won a record $1.6 billion of new business and reported milestone revenue of $1.12 billion and EPS of $1.00. Backlog grew 20% to $2.8 billion, which along with continuing investment in capabilities, talent and innovation in drug development, provides a solid foundation for further growth in 2013."

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release contains certain non-GAAP financial measures, including non-GAAP operating and net income and non-GAAP diluted earnings per share. While non-GAAP financial measures are not superior to or a substitute for the comparable GAAP measures, ICON believes certain non-GAAP information is useful to investors for historical comparison purposes.

ICON will hold its fourth quarter conference call today, February 19, 2013 at 9:00 EST [14:00 Ireland & UK]. This call and linked slide presentation can be accessed live from our website at http://investor.iconplc.com. A recording will also be available on the website for 90 days following the call. In addition, a calendar of company events, including upcoming conference presentations, is available on our website, under "Investors". This calendar will be updated regularly.

The statements made in this press release may contain forward-looking statements that involve a number of risks and uncertainties. In addition to the matters described in this press release, the ability to maintain large client contracts or enter into new contracts, maintain client relationships and the ability to manage the opening of new offices, the integration of new business mergers and acquisitions, as well as other risks and uncertainties detailed from time to time in reports filed with the US Securities and Exchange Commission by ICON, including its Form 20-F, F-1, S-8 and F-3, may affect the actual results achieved by ICON. ICON disclaims any intent or obligation to update these forward-looking statements.

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 79 locations in 37 countries and has approximately 10,045 employees. Further information is available at www.iconplc.com.